Allogeneic ABCB5-positive Limbal Stem Cells for Treatment of LSCD

Sponsor

RHEACELL GmbH & Co. KG (Industry)

Overall Status

Active, not recruiting

CT.gov ID

NCT03549299

Collaborator

FGK Clinical Research GmbH (Industry), Ticeba GmbH (Industry), Granzer Regulatory Consulting & Services (Other)

Enrollment

Locations

Arms

Anticipated Duration (Months)

3.2

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The aim of this clinical trial is to investigate the efficacy (by monitoring neovascularization and epithelial defects) of up to four doses of the investigational medicinal product (IMP) LSC2 topically administered on the target eye of patients with LSCD. Further, safety of the IMP during and after application will be investigated (by monitoring adverse events [AEs]).

Condition or Disease	Intervention/Treatment	Phase
Limbal Stem Cell Deficiency	Biological: LSC2	Phase 1/Phase 2

Detailed Description

This is an interventional, open-label, phase I/IIa clinical trial to investigate the efficacy and safety of up to four doses of the IMP topically administered on the target eye of patients with LSCD. Patients will be treated in up to four ascending dose groups.

The allogeneic investigational product LSC2 contains ABCB5-positive limbal stem cells (from corneal rims of cadaveric donors, expanded ex vivo, isolated and stored in a donor cell bank).

The IMP will be applied on the target eye. Prior to application, the conjunctival pannus will be removed under general or local anesthesia.

Patients will be followed up for efficacy for 1 year. Efficacy of the IMP will be monitored by assessing neovascularization and epithelial defects.

To assess long-term safety of LSC2 one follow-up visit at Month 24 post IMP application is included.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

16 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Patients will be treated in up to four ascending dose groups. After the first treated patient of the first dose group (Group A) was followed for 2 weeks, a safety and tolerability assessment of the applied IMP dose will be conducted by an internal committee. The same approach applies to the second subject. Dose escalation and recruitment of additional patients into the second dose group (Group B) will depend on the safety and tolerability of the IMP in Group A. A safety and tolerability assessment will be conducted after the last treated patient of the first dose group (Group A) was followed for 12 weeks. The same approach applies to Group C and D.Patients will be treated in up to four ascending dose groups. After the first treated patient of the first dose group (Group A) was followed for 2 weeks, a safety and tolerability assessment of the applied IMP dose will be conducted by an internal committee. The same approach applies to the second subject. Dose escalation and recruitment of additional patients into the second dose group (Group B) will depend on the safety and tolerability of the IMP in Group A. A safety and tolerability assessment will be conducted after the last treated patient of the first dose group (Group A) was followed for 12 weeks. The same approach applies to Group C and D.

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

An Interventional, Open-label, Multicenter Phase I/IIa Clinical Trial to Investigate the Safety and Efficacy of Ascending Doses of Allogeneic ABCB5-positive Limbal Stem Cells (LSC2) for the Treatment of Limbal Stem Cell Deficiency (LSCD)

Actual Study Start Date :

Jul 4, 2019

Anticipated Primary Completion Date :

Sep 1, 2021

Anticipated Study Completion Date :

Sep 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: LSC2; 7.5 x 10^4 cells Single dose of LSC2, 7.5 x 10^4 cells per patient	Biological: LSC2 Topical application of IMP on target eye Other Names: Suspension of ABCB5-positive limbal stem cells in pre-filled syringe
Experimental: LSC2; 3.0 x 10^5 cells Single dose of LSC2, 3.0 x 10^5 cells per patient	Biological: LSC2 Topical application of IMP on target eye Other Names: Suspension of ABCB5-positive limbal stem cells in pre-filled syringe
Experimental: LSC2; 8.0 x 10^5 cells Single dose of LSC2, 8.0 x 10^5 cells per patient	Biological: LSC2 Topical application of IMP on target eye Other Names: Suspension of ABCB5-positive limbal stem cells in pre-filled syringe
Experimental: LSC2; 1.2 x 10^6 cells Single dose of LSC2, 1.2 x 10^6 cells per patient	Biological: LSC2 Topical application of IMP on target eye Other Names: Suspension of ABCB5-positive limbal stem cells in pre-filled syringe

Outcome Measures

Primary Outcome Measures

Response rate at 12 months after IMP application [Month 12]
Response rate at 12 months after IMP application, where response is defined as: no or mild corneal neovascularization (no vessel penetration or vessel penetration up to 1 quadrant, without central cornea) AND no or mild epithelial defects (no corneal erosion or ulcer are present (corneal wounds are closed) or minimal superficial staining)
Assessment of adverse event (AE) occurrence [Up to 24 months.]
All AEs occurring during the clinical trial will be registered, documented and evaluated.

Secondary Outcome Measures

Response rate at 3 months after IMP application [Month 3]
Response rate at 3 months after IMP application, where response is defined as: no or mild corneal neovascularization (no vessel penetration or vessel penetration up to 1 quadrant, without central cornea) AND no or mild epithelial defects (no corneal erosion or ulcer are present (corneal wounds are closed) or minimal superficial staining)
Neovascularization [Baseline, week 1, 2, 3, 4, 5, 6, 7, 12, month 6 and 12]
Corneal neovascularization will be assessed as "none" (no blood vessel penetration), "mild" (blood vessel penetration of 1 quadrant, without central cornea involvement), "moderate" (blood vessel penetration of 1 quadrant, with central cornea involvement or blood vessel penetration of 2 or 3 quadrants, with or without central cornea involvement) or "strong" (blood vessel penetration of all quadrants, with or without central cornea involvement).
Epithelial defects [Baseline, week 2, 4, 6, month 3, 6 and 12]
Epithelial defects will be assessed as "none" (no corneal erosion or ulcer are present (corneal wounds are closed)) or "mild" (minimal superficial staining) or "moderate" (dense coalescent staining up to 2 mm in diameter) or "strong" (dense coalescent staining greater than 2 mm in diameter) by means of fluorescein staining.
Ocular symptoms of pain, photophobia, burning [Baseline, week 2, 4, 6, 12, month 6 and 12]
Photophobia and burning will be assessed as "no complaint" (grade 0), "mild" (grade 1), "moderate" (grade 2) or "severe" (grade 3). Pain assessment will be done by the patient using a 11-point numerical rating scale ranging between no pain (zero) and worst imaginable pain (ten).
Ocular inflammation [Baseline, week 2, 4, 6, 12, month 6 and 12]
The assessment of inflammation will be categorized as present (yes) or nonexistent (no).
Corneal opacity [Baseline, week 2, 4, 6, 12, month 6 and 12]
Corneal opacification will be assessed as "none" (no corneal opacification), "mild" (corneal opacification in up to 1 quadrant, without central cornea involvement), "moderate" (corneal opacification in 1 quadrant, with central cornea involvement or corneal opacification in 2 or 3 quadrants, with or without central cornea involvement) or "strong" (corneal opacification in all quadrants, with or without central cornea involvement). Additional densitometric Pentacam® measurements are optional. Opacity values of the following ring-shaped corneal segments will be record: 0 - 2 mm, 2 - 6 mm, 6 - 10 mm, 10 - 12 mm (anterior, central and posterior corneal layer for each segment) 0 - 2 mm, 2 - 6 mm, 6 - 10 mm, 10 - 12 mm (full thickness average for each segment) Anterior layer of the complete cornea (0 - 12 mm) Central layer of the complete cornea (0 - 12 mm) Posterior of the complete cornea (0 - 12 mm) Overall cornea (0 - 12 mm, full thickness)
Visual acuity [Baseline, week 2, 4, 6, 12, month 6 and 12]
Clarity of vision.
Quality of life assessment [Baseline, week 12, month 12]
Quality of life (visual function questionnaire-25 [VFQ-25]) questionnaire to be answered.
Physical examination [Baseline, week 12, month 12]
A full physical examination will be performed at week 12 and abnormal physical examination results will be evaluated and reported as AEs.
Tonometry [Baseline,week 1, 3, 7 and 12]
Vital signs: Body temperature at Baseline, week 12, month 12 [Baseline, week 12, month 12]
Body temperature at Baseline, week 12 and month 12 will be evaluated.
Vital signs: Blood pressure at Baseline, week 12, month 12 [Baseline, week 12, month 12]
Blood pressure at Baseline, week 12 and month 12 will be evaluated.
Vital signs: Heart rate at Baseline, week 12, month 12 [Baseline, week 12, month 12]
Heart rate at Baseline, week 12 and month 12 will be evaluated.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 85 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Male or female patients aged 18 to 85 years
Patients with secondary bilateral or unilateral LSCD (injury that caused LSCD at least 6 months prior to inclusion)
Neovascularization: Vessel penetration of at least 2 quadrants, with central cornea involved
Patients understand the nature of the procedure and are providing written informed consent prior to any clinical trial procedure
Women of childbearing potential must have a negative blood pregnancy test at Visit 1
Women of childbearing potential must be willing to use highly effective contraceptive methods during the course of the clinical trial

Exclusion Criteria:

Compromised eyelid mobility and/or symblepharon; patient can be re-screened after appropriate treatment
Presence of eyelid malposition; patient can be re-screened after appropriate treatment
Active local ocular or systemic infection and/or inflammation. Patient can be re-screened after infection and/or inflammation is resolved.
Tumor diseases or history of tumor disease
Active ocular neoplastic disease (exclusion will be based on investigator's assessment)
Corneal erosion or ulcer is bigger than 4 mm2; corresponding to less than 95% of continuous corneal epithelium. Patient can be re-screened after erosion or ulcer is resolved (≤ 4 mm2).
Positive for human immunodeficiency virus (HIV) 1 and/or 2 (diagnosed by serologic testing)
Clinically significant or unstable concurrent disease or other clinical contraindications to stem cell transplantation
History of glaucoma
Contraindications to trial related procedures/substances including
The surgical procedure (e.g. removing of the conjunctival pannus)
Contact lens complications due to contact lens use in the proposed trial (based on the Efron Grading scale for standard clinical reference for contact lens complications)
Tear secretion deficiency determined by Schirmer's test
Allergy, sensitivity or intolerance to components/excipients of the IMP/ per protocol pre-planned concomitant medications
Conjunctival scarring with fornix shortening
General anesthesia (in case general anesthesia is required) or local anesthesia
Immunosuppression (being mandatory concomitant therapy)
Intraocular pressure (IOP) of ≥30 mm Hg
History or clinical signs of stroke or transient ischemic attacks
Active or suspected ocular or periocular infections
Active or suspected intraocular inflammation
Further clinical contraindications to IMP application (exclusion will be based upon investigator's judgment)
Current or previous (within 30 days of enrollment) treatment with another IMP, or participation and/or under follow-up in another clinical trial
Previous participation in this clinical trial (except screening failure due to inclusion criterion 2 and/or exclusion criterion 1 and/or 2 and/or 3 and/or 6)
Known abuse of alcohol, drugs, or medicinal products
Patients unwilling or unable to comply with the requirements of the protocol
Lactating women
Evidence of any other medical conditions (such as psychiatric illness, physical examination, or laboratory findings) that may interfere with the planned treatment, affect the patient's compliance, or place the patient at high risk of complications related to the treatment
Employees of the sponsor, or employees or relatives of the investigator

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Massachusetts Eye and Ear Infirmary	Boston	Massachusetts	United States	02114
2	Universitäts-Klinikum Heidelberg, Kopfklinik	Heidelberg		Germany	69120
3	Universitäts-Klinikum Jena, Augenklinik	Jena		Germany	07747
4	Universitäts-Klinikum Köln, Augenklinik	Köln		Germany	50937
5	Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Augenklinik und Poliklinik	Mainz		Germany	55131